Assignee
OMEROS CORP
US·77 granted patents·133 pending applications·971 citations·filing 1999–2025
Top patents by PatentIndex Score
210 records- 0197US7973068B2Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammationOMEROS CORP·Filed 2002·Granted Jul 5, 2011·71 cites·1 claims
- 0297US7067144B2Compositions and methods for systemic inhibition of cartilage degradationOMEROS CORP·Filed 2003·Granted Jun 27, 2006·100 cites·41 claims
- 0397US6645168B2Arthroscopic irrigation solution and method for inhibition of pain and inflammationOMEROS CORP·Filed 2002·Granted Nov 11, 2003·78 cites·36 claims
- 0497US6420432B2Surgical irrigation solution and method for inhibition of pain and inflammationOMEROS CORP·Filed 2001·Granted Jul 16, 2002·83 cites·31 claims
- 0596US9644035B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2013·Granted May 9, 2017·18 cites·15 claims
- 0696US9475885B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2015·Granted Oct 25, 2016·15 cites·31 claims
- 0796US7919094B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2006·Granted Apr 5, 2011·86 cites·21 claims
- 0895US12030853B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted Jul 9, 2024·4 cites·14 claims
- 0995US6492332B1Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammationOMEROS CORP·Filed 2000·Granted Dec 10, 2002·126 cites·26 claims
- 1094US9278101B2Ophthalmologic irrigation solutions and methodOMEROS CORP·Filed 2014·Granted Mar 8, 2016·14 cites·13 claims
- 1193US9855246B2Stable preservative-free mydriatic and anti-inflammatory solutions for injectionOMEROS CORP·Filed 2016·Granted Jan 2, 2018·9 cites·15 claims
- 1293US9486406B2Stable preservative-free mydriatic and anti-inflammatory solutions for injectionOMEROS CORP·Filed 2015·Granted Nov 8, 2016·10 cites·13 claims
- 1393US9066856B2Stable preservative-free mydriatic and anti-inflammatory solutions for injectionOMEROS CORP·Filed 2013·Granted Jun 30, 2015·15 cites·16 claims
- 1493US2026035483A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2025·Application pending·0 cites
- 1592US11661418B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted May 30, 2023·4 cites·21 claims
- 1692US10745274B1Nucleic acids encoding antibodies specifically binding to MASP-3OMEROS CORP·Filed 2020·Granted Aug 18, 2020·2 cites·13 claims
- 1792US9399040B2Ophthalmologic irrigation solutions and methodOMEROS CORP·Filed 2013·Granted Jul 26, 2016·11 cites·3 claims
- 1892US2026049158A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2025·Application pending·0 cites
- 1991US8343970B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2011·Granted Jan 1, 2013·12 cites·42 claims
- 2091US7786139B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2008·Granted Aug 31, 2010·16 cites·13 claims
- 2190US11807641B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2020·Granted Nov 7, 2023·2 cites·18 claims
- 2290US9585895B2Ophthalmologic irrigation solutions and methodOMEROS CORP·Filed 2015·Granted Mar 7, 2017·5 cites·11 claims
- 2390US8377930B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2009·Granted Feb 19, 2013·11 cites·16 claims
- 2489US12195427B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2022·Granted Jan 14, 2025·1 cites·18 claims
- 2589US12091468B2Therapeutic antibodies that bind to the serine protease domain of MASP-2 and uses thereofOMEROS CORP·Filed 2023·Granted Sep 17, 2024·1 cites·18 claims
- 2689US8685975B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2012·Granted Apr 1, 2014·8 cites·40 claims
- 2788US11883493B2Antibodies specifically binding to MASP-3 for the treatment of various diseases and disordersOMEROS CORP·Filed 2021·Granted Jan 30, 2024·1 cites·17 claims
- 2888US11207275B2Treatment of addiction and impulse-control disorders using PDE7 inhibitorsOMEROS CORP·Filed 2018·Granted Dec 28, 2021·2 cites·14 claims
- 2988US10870708B2Methods for inhibiting angiogenesis in a subject in need thereofOMEROS CORP·Filed 2017·Granted Dec 22, 2020·3 cites·3 claims
- 3088US9220715B2Treatment of addiction and impulse-control disorders using PDE7 inhibitorsOMEROS CORP·Filed 2013·Granted Dec 29, 2015·5 cites·34 claims
- 3188US2025059299A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2024·Application pending·0 cites
- 3287US11584714B2MASP-2 inhibitors and methods of useOMEROS CORP·Filed 2019·Granted Feb 21, 2023·5 cites·13 claims
- 3387US11027015B2Antibodies specifically binding to MASP-3 for the treatment of various diseases and disordersOMEROS CORP·Filed 2020·Granted Jun 8, 2021·1 cites·19 claims
- 3487US10059776B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2017·Granted Aug 28, 2018·2 cites·14 claims
- 3587US2024342278A1Antibodies specifically binding to masp-3 for the treatment of various diseases and disordersOMEROS CORP·Filed 2023·Application pending·0 cites
- 3686US2024228665A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 3786US2026062498A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2025·Application pending·0 cites
- 3886US2024254257A1Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and DisordersOMEROS CORP·Filed 2023·Application pending·0 cites
- 3985US11981749B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2020·Granted May 14, 2024·1 cites·8 claims
- 4085US11525011B2Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndromeOMEROS CORP·Filed 2019·Granted Dec 13, 2022·1 cites·12 claims
- 4185US9677070B2Composition and method for diversification of target sequencesOMEROS CORP·Filed 2013·Granted Jun 13, 2017·6 cites·28 claims
- 4285US9434707B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2015·Granted Sep 6, 2016·3 cites·1 claims
- 4385US2024076409A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2023·Application pending·0 cites
- 4484US7091181B2Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptorsOMEROS CORP·Filed 2001·Granted Aug 15, 2006·22 cites·16 claims
- 4584US6413961B1Irrigation solution and method for inhibition of pain and inflammationOMEROS CORP·Filed 1999·Granted Jul 2, 2002·51 cites·23 claims
- 4683US12351648B2Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndromeOMEROS CORP·Filed 2021·Granted Jul 8, 2025·1 cites·6 claims
- 4783US11453709B2Chimeric inhibitor molecules of complement activationOMEROS CORP·Filed 2020·Granted Sep 27, 2022·1 cites·10 claims
- 4883US11234965B2Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditionsOMEROS CORP·Filed 2019·Granted Feb 1, 2022·1 cites·6 claims
- 4983US9102643B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2014·Granted Aug 11, 2015·3 cites·1 claims
- 5083US6740100B2Tendon repair using adhesiveOMEROS CORP·Filed 2002·Granted May 25, 2004·124 cites·19 claims
Showing the top 50 of 210 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when OMEROS CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →